Wang et al. [51] demonstrated in a randomized trial involving patients with complete LBBB and non-ischemic cardiomyopathy that implantation of LBBAP for CRT resulted, after six months, in a 5.6-percentage-point greater increase in LVEF compared to conventional BVP, and a significantly greater reduction in LVESV (by 25 mL) and NT-proBNP (by 1.07 ng/mL), with comparable improvement in the NYHA functional class and similar QRS narrowing. Here, NPPB is linked to ischemic cardiomyopathy.